RetroSense Therapeutics is a privately-held biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The Company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. RetroSense has worldwide exclusive rights to the relevant intellectual property from both institutions. RetroSense is led by a team of seasoned veterans with deep experience in taking products from the discovery stage through to the clinic.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/12/15 | $6,000,000 | Series A |
Blue Water Angels Michigan Economic Development Corp. Nerveda SDL Capital Tech Coast Angels | undisclosed |
| 11/13/15 | $6,000,000 | Series B |
Blue Water Angels ExSight Capital RBV Capital Santen Pharmaceuticals | undisclosed |
